share_log

HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

Benzinga ·  Sep 18, 2023 18:31

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Oncternal Therapeutics (NASDAQ:ONCT) from Neutral to Buy and announces $2 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment